Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anika Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed orthopedic products company centered on hyaluronic-acid-based OA Pain Management and Regenerative Solutions. Its 8-K filings report operating and financial results, guidance updates, material events, clinical and regulatory disclosures for Hyalofast, and governance matters involving board and executive transitions.
Proxy materials describe shareholder voting matters, board structure, executive compensation, corporate governance practices, and the company’s focused portfolio following completed portfolio actions. The filings also identify ANIK common stock, capital-structure disclosures, risk and operating topics, and channel-based business reporting for Commercial Channel and OEM Channel activity.
Anika Therapeutics EVP and General Counsel David Colleran reported routine equity compensation activity tied to previously granted restricted stock units (RSUs). On March 9, 2026, 5,465 RSUs from a March 9, 2023 grant vested and were converted into an equal number of common shares at no exercise price.
To cover tax withholding on the vesting, 1,919 common shares were retained by the company at a price of $14.96 per share, as a tax-withholding disposition rather than a market sale. After these transactions, Colleran directly holds 53,100 shares of Anika Therapeutics common stock.
Anika Therapeutics director Cheryl R. Blanchard reported the vesting of 20,001 restricted stock units into common shares. Each RSU converts into one share of common stock, and this represents the third and final installment of a 60,004-unit award granted on March 9, 2023.
Of the vested shares, 5,871 were withheld by the company at $14.96 per share to cover tax obligations, leaving a net increase of 14,130 shares. Following these transactions, Blanchard holds 211,450 shares directly and an additional 11,742 shares indirectly through a revocable trust of which she is the sole trustee and a beneficiary.
Anika Therapeutics, Inc. SVP, CAO & Treasurer Ian McLeod completed the final vesting of a prior RSU grant and related tax withholding. On March 9, 2026, 2,197 restricted stock units converted into 2,197 shares of common stock, representing the third and final installment of a 6,590‑RSU award granted on March 9, 2023. To cover tax obligations on this vesting, 639 shares were retained by the company at a price of $14.96 per share, leaving a net 1,558 shares from this tranche. After these transactions, McLeod directly holds 18,744 shares of Anika Therapeutics common stock.
Anika Therapeutics outlines a major strategic shift toward osteoarthritis (OA) pain management and regenerative orthopedic solutions built on its hyaluronic acid (HA) technology. The company has exited earlier acquisitions by selling Arthrosurface for a ten‑year, non‑interest‑bearing $7.0 million promissory note plus potential contingent payments, and Parcus Medical for $4.5 million in cash, sharpening focus on higher‑priority HA programs.
Growth is centered on OA products Monovisc and Orthovisc, marketed in the U.S. through a long‑standing exclusive partnership with J&J MedTech, which accounted for 50% of 2025 revenue, and on the Integrity Implant System for tendon augmentation, which is gaining surgical adoption. Anika is advancing Cingal toward a U.S. NDA with ongoing bioequivalence work and pursuing FDA approval of Hyalofast after submitting a PMA, though the FDA has issued a deficiency letter the company is working to address. Research and development spending rose to $25.8 million in 2025 to support these regulatory and clinical programs, while the 10‑K also highlights competitive pressures, manufacturing and supply‑chain concentration, heavy customer reliance, and extensive global regulatory, reimbursement, cybersecurity, data‑privacy, and product‑liability risks.
Anika Therapeutics reported fourth quarter and full-year 2025 results and outlined leadership transition plans for its General Counsel. Q4 2025 revenue was $30.6 million, essentially flat year over year, with gross margin expanding to 63%. Commercial Channel revenue grew 22% while OEM Channel revenue declined 12%.
For full-year 2025, revenue was $112.8 million, down 6% from 2024, but gross margin improved to 57%. The company generated $11.2 million in operating cash flow and $4.4 million in free cash flow, and reduced its net loss to $10.9 million from $56.4 million in 2024. Adjusted EBITDA was $5.3 million in 2025 versus $15.5 million in 2024.
Anika continued a $15 million Rule 10b5-1 share repurchase program, funding $10.7 million to date and expecting completion in the second quarter of 2026. The company received an FDA response to its Hyalofast PMA in January 2026 and is preparing follow-up submissions, while progressing remaining requirements for the Cingal NDA. Separately, Anika entered a Transition Agreement under which Executive Vice President, General Counsel and Corporate Secretary David Colleran will remain in his role through May 1, 2026, with continued salary, benefits, and equity vesting, and will receive separation benefits pursuant to his Executive Retention Agreement in exchange for a general release of claims.
Anika Therapeutics President and CEO Stephen D. Griffin, who is also a director, reported new equity awards effective February 1, 2026. He was granted 310,207 stock appreciation rights with an exercise price of $9.23 and 130,402 restricted stock units.
Both the stock appreciation rights and RSUs were awarded at no cash cost to him and are granted under Anika’s 2017 Omnibus Incentive Plan. They vest in three equal annual installments, beginning on February 1, 2027, conditioned on his continued service.
Following these awards, Griffin directly holds 10,671 shares of Anika common stock, which includes 800 shares acquired on November 14, 2025 through the company’s Employee Stock Purchase Plan. The stock appreciation rights may be settled in cash, shares, or a combination, and each RSU represents the right to one share or the cash equivalent on vesting.
Caligan Partners and David Johnson report their current stake in Anika Therapeutics, Inc. on Amendment No. 5 to Schedule 13D. They report beneficial ownership of 1,435,130 shares of Anika common stock, representing 9.95% of the outstanding class, with shared voting and dispositive power over all these shares.
The filing also describes additional economic exposure through cash-settled swap agreements. Caligan-related funds hold derivative agreements referencing 623,621 Anika shares, providing economic results comparable to ownership for about 4.3% of the common stock. These swaps do not give voting or dispositive power, and the reporting persons explicitly disclaim beneficial ownership of the referenced shares.
Anika Therapeutics, Inc. filed a report detailing a leadership transition while reaffirming its guidance for the year ended December 31, 2025, including expectations that Adjusted EBITDA margin will range from positive 3% to negative 3% of revenue.
The company announced that President and Chief Executive Officer Cheryl R. Blanchard will step down from the CEO role effective February 1, 2026, moving to Executive Chair for twelve months, then Special Advisor for six months, and remaining an employee through January 31, 2028. Under a transition agreement, she will receive cash severance equal to 18 months of base salary paid over 24 months and continued eligibility for benefits and equity vesting during her service.
Steve Griffin, currently Executive Vice President, Chief Financial Officer and Chief Operating Officer, has been appointed President and Chief Executive Officer effective February 1, 2026 and will also join the Board as a Class III director. His new employment agreement provides a $690,000 annual base salary, a target annual bonus equal to 75% of base salary starting in 2026, and equity awards with a target grant date fair value of $2,450,000 in restricted stock units and stock appreciation rights vesting over three years. Director Susan N. Vogt will resign from the Board effective February 1, 2026 with no reported disagreements, and the company has entered into indemnification agreements with each director.
Anika Therapeutics, Inc. received an updated ownership report on its common stock from Trigran Investments, Inc. and related individuals on 12/31/2025. The group reports beneficial ownership of 168,400 shares of common stock, representing 1.2% of the outstanding class.
The filing shows no sole voting or dispositive power, with all voting and dispositive authority reported as shared. Each reporting person states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Anika. They also disclaim beneficial ownership of the shares except to the extent of any pecuniary interest.
Anika Therapeutics, Inc. registered 475,000 additional shares of common stock on Form S-8 for issuance under its 2017 Omnibus Incentive Plan. The increase in the plan reserve was approved by the Board and subsequently approved by stockholders on June 20, 2025.
The newly registered shares are the same class as those covered by prior S-8 registrations for this plan, allowing continued grants under the company’s equity compensation program.
Anika Therapeutics, Inc. registered 475,000 additional shares of common stock on Form S-8 for issuance under its 2017 Omnibus Incentive Plan. The increase in the plan reserve was approved by the Board and subsequently approved by stockholders on June 20, 2025.
The newly registered shares are the same class as those covered by prior S-8 registrations for this plan, allowing continued grants under the company’s equity compensation program.